Clinical Trial

Disease: Non-Hodgkin Lymphoma, NHL, (NCT05332054)

Disease info:

Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. NHL is a term that is used for many different types of lymphoma that all share some of the same characteristics. NHL usually starts in lymph nodes or other lymph tissue, but it can sometimes affect the skin. 

B-cell lymphoma refers to types of non-Hodgkin lymphoma that are characterised by abnormalities of the "B cells" (a type of white blood cell that makes antibodies to help fight infection). The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms.

Frequency:
Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. About 77,240 people (42,380 males and 34,860 females) will be diagnosed with NHL. This includes both adults and children.
Official title:
A Study to Evaluate Long-Term Safety of CAR-T Cell Therapy in Patients With Hematologic Malignancies
Who:
Sponsor:

Caribou Biosciences, Inc.

Partners:
Locations:

United States, California

University of California Irvine
Irvine, California, United States, 92868

 

United States, Ohio

Oncology Hematology Care
Cincinnati, Ohio, United States, 45242

 

United States, Texas

Baylor Research InstituteDallas, Texas, United States, 75246

MD Anderson Cancer Center, Houston, Texas, United States, 77030

Study start:
Mar. 16, 2022
Enrollment:
100
Gene editing method:
CRISPR-Cas
Type of edit:
Gene knock-out
Gene:
Programmed Cell Death 1 (PD1), T Cell Receptor (TCR), CD19-specific CAR
Delivery method:
- Ex-vivo
Trial link:
https://clinicaltrials.gov/ct2/show/NCT05332054
Safety updates:

(12-07-2021) Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

(08-09-2020) Caribou Biosciences Announces FDA Clearance of its IND for CB-010, an Off-the-shelf Allogeneic Anti-CD19 CAR-T Cell Therapy

Note:
Undisclosed
Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Enrolling by invitation

Description

This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients with hematologic malignancies. The purpose of this 15-year research study is to collect long-term observational data to identify and understand potential late side effects in patients who have received CAR-T cell therapies as part of a previous Caribou-sponsored study or a Caribou-sponsored special access programme.

Last updated: Sep. 8, 2023
close
Search CRISPR Medicine